BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bio-Rad Laboratories, Inc. (BIO) Introduces TC20™ Automated Cell Counter


9/17/2012 10:39:53 AM

Hercules, CA — September 17, 2012—Bio-Rad Laboratories, Inc. today announced the launch of its TC20 automated cell counter, the next generation of the company’s TC10™ automated cell counter that provides accurate and reliable counts of live mammalian cells in 30 seconds. The TC20 system’s improved lens and cell counting algorithm make it compatible with a broader range of cell sizes and types. This includes cells smaller than 10 microns and complex samples such as stem cells and primary cells derived from tissue or blood.

Stem cell research, toxicology studies, and flow cytometry all rely on an accurate and consistent number of input cells. Counting cells prior to cell culture or before starting processes and analytical techniques used in such work is extremely tedious if done manually with a hemocytometer. Manually counting cells is also subject to user bias, which can lead to variable results among researchers.

Many of the advanced features of the TC10 system, such as the auto-focus technology that provides highly reproducible cell counts with reduced user-to-user variability, remain in the TC20 system. The TC20 also has the ability to analyze cells across multiple focal planes, which eliminates live cell undercounting associated with single focal plane analysis. And unlike electrical impedance-based counters, researchers can view cells in real time to immediately confirm their total and live/dead cell counts.

Additional features new to the TC20 automated cell counter include:

Cell size gates — enable accurate counting of such complex samples as primary cells, which are composed of multiple cell populations

TC20 data analyzer — offers post-count analysis, such as histograms, and comparative analysis with multiple samples and reporting

Automated data export — lets the user export count data to a USB flash drive to be analyzed using the TC20 data analyzer

Although the TC10 is no longer available, the counting slides, trypan blue dye, thermal printer, and verification kit developed for that system are compatible with the TC20 system.

Visit http://bit.ly/OTbe0s to see how the TC20 automated cell counter works. For more information on Bio-Rad’s product portfolio, please visit www.biorad.com/tc20.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:

Steve Kulisch

Bio-Rad Laboratories, Inc.

510-741-5638

Steve_Kulisch@bio-rad.com

Ken Li

Chempetitive Group

312-997-2436 x 112

kli@chempetitive.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES